The latest headlines across every section, pulled from official and open-access sources.
Clinical AI startup Abridge held a New York City event to signal it’s done being thought of as just an AI scribe. The company announced a Nvidia foundation model partnership, an Eli Lilly investment, new capabilities for its platform, and the intent to help mediate the relationship between payers and providers. The post Abridge Goes Beyond Documentation: 4 Updates appeared first on MedCity News .
Public Health
Critical Care Medicine
This cross-sectional study examines the use of long-acting injectable antiretroviral therapy among Medicare beneficiaries with HIV and characterizes the differences between people receiving oral antiretroviral therapy vs long-acting injectable antiretroviral therapy.
This quality improvement study examines the outcomes associated with a pilot telemedicine program for incarcerated individuals with diabetes in Illinois.
This cross-sectional study examines chronic conditions and mortality in fee-for-service Medicare and Medicare Advantage in 2019 and 2022, before and after the COVID-19 pandemic.
This cross-sectional study estimates the prevalence of visual impairment in US Hispanic and Latino adults with diverse backgrounds and explores whether it is associated with risk factors for cardiovascular disease.
This cross-sectional study estimates the association between implementation of point-of-sale comprehensive background check policies in 6 states—Colorado, Delaware, New Mexico, Oregon, Vermont, and Washington—and county-level firearm homicide rates.
This cross-sectional study of survey data from adults living in communities impacted by mass violence examines whether greater mass violence incident–related media consumption is associated with worry and avoidance behaviors associated with concerns about future violence.
This cohort study evaluates whether administration of 30 mL/kg or more of fluid within 6 hours of hospital arrival is associated with reduced 30-day mortality in adults with community-onset sepsis.
This Special Communication assesses National Institutes of Health–supported research projects focusing on ultraprocessed foods (UPF) for fiscal years 2016 to 2025 to identify critical gaps in UPF research and explore opportunities for advancements in the field.
Strategy aims to deliver 5,000 new walking, wheeling and cycling routes and 10,000 safer crossings over the next 5 years.
Two-dose MenB vaccine to be offered to young people ahead of the autumn as part of a one-off vaccination programme in England.
At AHIP 2026, healthcare leaders raised concerns about CMS’ new Medicaid eligibility requirements, with one urging the agency to give states more time to implement them. The post Healthcare Leader to CMS on New Medicaid Eligibility Requirements: Give States an Extension appeared first on MedCity News .
Total Nutrition Inc. of Deer Park, NY is voluntarily expanding its recall of TNVitamins and Doctor's Pride Ultra Potent Complete Green Superfood Moringa Capsules due to the potential to be contaminated with Salmonella. This expansion follows an ongoing supply chain investigation that identified addi
Frequently requested or proactively posted drug-specific and other records
Section 505B(d)(1) requires FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA by the final due date, have failed to seek or obtain a deferral or deferral extension.
International Council for Harmonisation - Safety
FDA's annual public meeting and opportunity for public comment on “Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments” will be held on June 23, 2026
Novartis said its RNA therapy del-brax met goals of a Phase 1/2 study in facioscapulohumeral muscular dystrophy (FSHD), an inherited muscle disorder that currently has no FDA-approved medicines. Del-brax is one of three RNA therapies from Novartis’s $12 billion acquisition of Avidity Biosciences. The post Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease appeared first on MedCity News .
Discover FDA's comprehensive list of registered outsourcing facilities engaged in human drug compounding. Get the latest updates, compliance guidelines, and resources to ensure safe, high-quality compounded medications. Explore regulations and stay informed with verified facility details.
Voriconazole and Liposomal Amphotericin B Availability Information
This report describes using a transmission model to project Ebola outbreak growth over three months.
This report describes a large outbreak of Bundibugyo virus disease identified in the Democratic Republic of the Congo and Uganda.